Mycoplasma qPCR Testing for Biologics

Last updated: August 4, 2026

Mycoplasma qPCR testing is a nucleic acid amplification approach used to detect Mycoplasma-related DNA in biologics and cell-culture samples. Method selection should be based on intended use, target coverage, limit of detection, matrix suitability, controls, and laboratory validation. A supplier study supports evaluation but does not replace user-specific method suitability or compendial testing decisions.

Mycoplasma contamination can affect cell substrates, biological materials, and manufacturing processes without producing the turbidity expected from many conventional bacteria. Nucleic acid testing can shorten the time to a result compared with culture-based workflows, but speed alone does not establish that an assay is suitable for a particular sample or regulatory use.

USP General Chapter <77> addresses validation and use of qualitative nucleic acid amplification tests for detecting Mycoplasma contamination. It includes method-suitability considerations, defined controls, and test strains. USP also maintains separate chapters for Mycoplasma tests and sterility tests. A laboratory should therefore define what the qPCR method is intended to do before treating it as an alternative, supplementary, or in-process method.

This guide explains the evidence an IVD, biopharmaceutical, or cell-therapy manufacturer should review when evaluating a mycoplasma qPCR assay. It is educational content and does not establish that a particular Biori product complies with a pharmacopeia or regulatory requirement.

What is mycoplasma qPCR testing used for?

Mycoplasma qPCR testing detects defined nucleic acid targets associated with the organisms covered by an assay’s primer and probe design. Depending on the validated intended use, testing may support raw-material assessment, cell-bank or cell-substrate testing, process monitoring, investigation of suspected contamination, or testing of biological manufacturing samples.

The phrase “mycoplasma testing” is sometimes used broadly, but target coverage is assay-specific. A method should not be assumed to detect every organism commonly grouped under Mycoplasma or Mollicutes terminology. Spiroplasma coverage should be checked explicitly rather than inferred from the assay name.

How should LoD be evaluated for a mycoplasma NAT?

The limit of detection, or LoD, is the lowest evaluated level at which the target is detected with the study’s defined probability or replicate performance. A useful LoD statement identifies the organism or reference material, concentration unit, matrix, sample preparation, number of replicates, instrument, and result rule.

For organism-based studies, values reported in CFU/mL are connected to the preparation and assignment of the reference material. They should not be treated as directly interchangeable with genome copies, DNA mass, or results from a different strain and workflow. Review the entire experimental context before comparing two supplier values.

An LoD study should also be distinguished from a quantitation claim. A qualitative mycoplasma NAT may demonstrate reliable detection at a low level without establishing quantitative accuracy across a calibration range.

What organism coverage should be reviewed?

Coverage evaluation has two complementary parts:

1. Inclusivity asks whether the assay detects the intended target organisms or sequence variants.
2. Exclusivity and cross-reactivity ask whether non-target biological materials produce an unintended positive result.

A supplier may support inclusivity with sequence analysis, wet testing, or both. The evidence should identify the databases, sequence set, acceptance criteria, test strains, and experimental conditions. A large coverage number is difficult to assess without the underlying sequence or strain evidence, so species counts should not replace a review of the actual panel.

Cross-reactivity testing should be relevant to the manufacturing environment and sample type. The absence of a signal in a selected non-target panel supports that study; it does not prove the assay can never react with an untested organism or material.

How is matrix suitability assessed?

Cell-culture media, sera, cryopreservation components, process additives, proteins, salts, and sample-treatment reagents can affect extraction or amplification. Matrix suitability is therefore a property of the complete workflow, not only the qPCR master mix.

A practical evaluation compares target-spiked samples and suitable controls in representative matrices. The study should show whether the target remains detectable and whether the internal control performs within its defined acceptance range. If inhibition is observed, the method may require extraction, dilution, additional purification, or a matrix-specific validation strategy.

Supplier matrix studies can help select a starting method, but users should evaluate their own formulation, cell density, sampling point, instrument, and preparation procedure before routine adoption.

Which controls should be included?

A qualitative mycoplasma qPCR workflow normally requires controls that separate a valid negative result from reaction failure or contamination. The exact design depends on the method, but the control strategy commonly considers:

• a positive control to confirm target detection;
• a non-template control to monitor reagent or setup contamination;
• a negative extraction control where sample preparation is part of the method;
• an internal control to identify extraction loss or amplification inhibition;
• defined acceptance criteria and invalid-result rules for every run.

Controls should be reviewed together. For example, a target-negative sample cannot be interpreted as valid solely because the non-template control is negative; the internal control must also support that the sample reaction functioned as intended.

What else should be checked before routine adoption?

Precision and reproducibility

Review variation across reagent lots, operators, instruments, days, and relevant target levels. A low-level sample is particularly useful because it challenges the method near its decision point. Precision evidence from a supplier should be verified within the user’s laboratory and workflow.

Robustness

Robustness studies examine defined variations such as reaction timing, temperature, reagent volume, extraction conditions, or instrument settings. The selected factors should reflect realistic sources of routine variation rather than arbitrary changes.

Instrument and software requirements

Confirm optical channels, passive-reference settings where applicable, reaction volume, cycling program, threshold method, and software rules. “Compatible” should mean that the specific instrument and analysis workflow have been evaluated or can be verified by the user.

Documentation and change control

Request the current instruction manual, COA, MSDS, validation information, storage and transport conditions, batch traceability information, and applicable change-control communication. Product documentation should remain aligned with the catalog number and formulation being evaluated.

Selected Biori product-specific validation data

Biori offers a Mycoplasma-focused qPCR kit and a separate Spiroplasma qPCR kit. The selected results below are product-specific observations, not universal performance guarantees. The full Data sections on the product pages provide the study context and detailed tables.

These values were verified against the current public product Data sections on August 4, 2026. Users should review the complete evidence and confirm suitability with representative samples before routine use.

Is Spiroplasma covered by every mycoplasma assay?

No coverage assumption should be made from the word “mycoplasma” alone. An assay detects the organisms supported by its primer/probe design and validation evidence. If Spiroplasma is a relevant risk, review whether the supplier’s sequence analysis and wet-testing panel explicitly include the required species and strains.

A separate Spiroplasma-targeted assay can make the intended target clearer, but it still requires evaluation of LoD, specificity, matrix suitability, controls, and user-laboratory performance.

Can qPCR replace compendial mycoplasma or sterility tests?

Not automatically. qPCR is a nucleic acid amplification technology, while compendial chapters define particular test purposes, method expectations, validation considerations, and acceptance frameworks. USP lists Mycoplasma tests and sterility tests in separate chapters, and USP <77> addresses qualitative NAT validation and testing for Mycoplasma contamination.

Whether a qPCR method can be used as an alternative, supplementary, rapid, or in-process method depends on the applicable jurisdiction, product, intended use, validation package, comparability strategy, and quality-system approval. A supplier’s product data do not by themselves establish regulatory acceptability for a user’s product.

Supplier-evaluation checklist

Before selecting a mycoplasma qPCR kit, confirm that the evidence supports the actual testing workflow.

1. Define the sample type, manufacturing stage, and intended decision.
2. Review the intended targets and the actual inclusivity evidence.
3. Check the LoD organism, unit, matrix, preparation method, replicates, and detection rule.
4. Review the non-target and cross-reactivity panel.
5. Evaluate representative matrices and the internal-control strategy.
6. Confirm positive, negative, extraction, and inhibition controls with acceptance rules.
7. Review precision, robustness, instruments, software, and lot information.
8. Request the current manual, COA, MSDS, validation summary, and change-control information.
9. Verify performance in the user’s laboratory before routine adoption.
10. Document how the selected method fits the applicable quality and regulatory strategy.

Frequently asked questions

What is mycoplasma qPCR testing used for in biologics manufacturing?

It is used to detect defined Mycoplasma-related DNA targets in samples such as cell substrates, cell-culture materials, process samples, or biological manufacturing materials. The appropriate use depends on the assay’s validation, the sample matrix, and the manufacturer’s contamination-control and quality strategy.

What is the difference between mycoplasma qPCR and mycoplasma NAT?

NAT is the broader term for nucleic acid testing. qPCR is one NAT platform that amplifies and detects target nucleic acids in real time. Other NAT formats may use different amplification or detection technologies.

Does a lower LoD always mean a better assay?

No. LoD is important, but it must be interpreted with target coverage, matrix suitability, controls, specificity, reproducibility, sample preparation, and the intended use. Values generated with different organisms, units, matrices, and replicate designs may not be directly comparable.

Why is an internal control important?

An internal control can reveal extraction loss or amplification inhibition. Without a valid internal-control result, a target-negative sample may be uninterpretable because the reaction may not have functioned correctly.

Is Spiroplasma automatically included in a mycoplasma assay?

Not necessarily. Review the assay’s target design, sequence analysis, strain panel, and product-specific evidence. If Spiroplasma is relevant to the risk assessment, confirm explicit coverage rather than relying on the product category name.

Does supplier validation remove the need for method suitability testing?

No. Supplier studies support evaluation and method selection. Users should confirm performance with their own sample matrix, preparation procedure, instrument, operators, acceptance criteria, and quality system.

Discuss your mycoplasma testing workflow

Biori can discuss the target organisms, sample matrix, sensitivity requirement, controls, documentation, and evaluation plan for a Mycoplasma or Spiroplasma qPCR workflow.

• Review the Mycoplasma DNA Detection Kit (qPCR), BP-QN22.
• Review the Spiroplasma DNA Detection Kit (qPCR), BP-QN299.
• Review Biori’s Manufacturing & Quality information.
• Use the qPCR Results Analysis Guide when defining amplification-curve and control review rules.
• Browse the Resources & Insights library.
• Contact Biori to request a technical discussion, quotation, sample evaluation, or documentation package.

References

1. United States Pharmacopeia. USP General Chapter <77>, Mycoplasma Nucleic Acid Amplification Tests.
2. United States Pharmacopeia. Microbiology Standards and Chapters.
3. United States Pharmacopeia. USP General Chapter <1229.17>, Mycoplasma Sterilization.
4. U.S. Food and Drug Administration. Biotechnology Inspection Guide.